Milestone Pharmaceuticals' stock fell 50% after the FDA's CRL for CMC issues, but the drug Etripamil has shown efficacy and ...

Stock analysts at HC Wainwright lifted their Q1 2025 earnings estimates for Milestone Pharmaceuticals in a report issued on Tuesday, April 1st. HC Wainwright analyst P. Trucchio now anticipates that ...

ORMP READ THE FULL ORMP RESEARCH REPORT Planning Spin-off / IPO of JV Company Oramed Pharmaceuticals (NASDAQ:ORMP) formed a JV with Hefei Tianhui Biotech (HTIT), OraTech Pharmaceuticals, which is a ...

Milestone Pharmaceuticals stock opened at $0.80 on Tuesday. Milestone Pharmaceuticals has a 52 week low of $0.71 and a 52 week high of $2.75. The company’s 50 day moving average price is $1.92 ...

TD Cowen downgraded Milestone Pharmaceuticals (MIST) to Hold from Buy and suspended the firm’s price target after Milestone announced the FDA issued a Complete Response Letter regarding its New ...

Investing.com -- TD Securities downgraded Milestone (WA:MMD) Pharmaceuticals (NASDAQ:MIST) to "Hold" and suspended its price target, citing regulatory uncertainty and commercialization challenges for ...

On Tuesday, TD Cowen analysts lowered the stock rating for Milestone Pharmaceuticals (NASDAQ:MIST) from Buy to Hold. The change comes following the company’s receipt of a Complete Response Letter (CRL ...

Investing.com -- TD Securities downgraded Milestone (WA:MMD) Pharmaceuticals (NASDAQ:MIST) to "Hold" and suspended its price target, citing regulatory uncertainty and commercialization challenges for ...

Investing.com -- TD Securities downgraded Milestone Pharmaceuticals (NASDAQ:MIST) to "Hold" and suspended its price target, citing regulatory uncertainty and commercialization challenges for its ...

In 2025, the CNS market is forecast to surpass $80bn in sales for the first time since 2013, marking a significant turnaround ...